Aim This study aims to investigate the seroconversion of antibodies against SARS-CoV-2 infection in pregnant women during their first and third trimesters, specifically during the second wave of the COVID-19 pandemic. Methodology This is a longitudinal follow-up study of pregnant women during the second peak of the COVID-19 pandemic. Patients in their first trimester (six to 12 weeks) were tested for SARS-CoV-2 IgM and IgG levels, with a repeat test conducted in the third trimester (28-40 weeks) using the automated VIDAS® (bioMérieux SA, Marcy-l'Étoile, France) system.
View Article and Find Full Text PDFObjectives: This study aims to describe the indications, complications, yield, and safety of amniocentesis beyond 24 weeks for prenatal diagnostic procedures along with the associated maternal and fetal outcomes.
Methods: A retrospective analysis was conducted on 60 pregnant women (with 61 fetuses) who underwent amniocentesis at or beyond 24 weeks from March 2021 to June 2023 at a tertiary care referral center. Data was collected from medical records and individual patient followups.
Pregnancy Hypertens
December 2024
Objectives: To evaluate a commercial a Congo Red urine devise for assessing preeclampsia risk.
Study Design: Prospective non-intervention study among women presenting with clinical suspicion of preeclampsia. The devise was used at the time of enrolment and, depending on gestation, on 1-3 later occasions.